Zyla Life Sciences

Zyla Life Sciences is a commercial life sciences company dedicated to developing and marketing a range of therapies for patients and healthcare providers. It offers various treatments targeting different types of pain and inflammation. Its commercial products include: 1. SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug (NSAID) indicated for adult patients for the short-term management of moderate to moderately severe pain where analgesic use on opioids is required; 2. ZORVOLEX, a formulation of diclofenac; 3. VIVLODEX, an SoluMatrix formulation of meloxicam approved for osteoarthritis pain; 4. TIVORBEX, a low-dose SoluMatrix indomethacin formulation for mild to moderate acute pain in adults; 5. INDOCIN Suppositories; 6. INDOCIN Oral Suspension products; 7. OXAYDO, an immediate-release oxycodone product indicated for the treatment of severe acute and chronic pain where opioid analgesics are required and alternative treatments are inadequate. Additionally, its pipeline includes Egalet-003, an AD stimulant candidate, and Egalet-004, an AD, ER hydrocodone-based product. The company was formerly known as Egalet Corporation, founded in 2010, with its headquarters in Wayne, Pennsylvania. On May 20, 2020, the company merged with Assertio Therapeutics and operates under the latter's name.